Trials / Completed
CompletedNCT02732639
A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)
Open-label, Multicenter, Trial Evaluating Efficacy and Safety of Peginterferon Alfa-2a (PEGASYS®) in Patients With Chronic Hepatitis D (CHD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the efficacy and safety of 48-week treatment with pegylated interferon (PEG-IFN) alfa-2a (Pegasys) monotherapy in participants with chronic hepatitis D (CHD). Treatment was followed by 24 weeks of treatment-free follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated Interferon (PEG-IFN) alfa-2a | Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks. |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2016-04-08
- Last updated
- 2016-08-26
- Results posted
- 2016-08-26
Locations
7 sites across 1 country: Romania
Source: ClinicalTrials.gov record NCT02732639. Inclusion in this directory is not an endorsement.